UK-based biopharmaceutical company AstraZeneca has announced a $3.5bn investment to expand its research and manufacturing ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

The jobs include roles in engineering and technical services and global supply chain functions. Read more at straitstimes.com ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

The decision to pause its investment in Britain came as AstraZeneca announced plans to spend $3.5bn (£2.7bn) expanding its US ...

The group’s shares have tumbled after it emerged that the firm’s China president has been detained as Chinese authorities ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

AstraZeneca today announces $3.5 billion of capital investment ... the relationship that exists between a patient/site ...

AstraZeneca Plc (NASDAQ: AZN) Q3 2024 Earnings Call Nov 12, 2024, 9:00 a.m. ET ...